2024-09-18 - Analysis Report
## Gilead Sciences, Inc. (GILD) Stock Analysis Report

**Company Overview:** Gilead Sciences is a biopharmaceutical company focused on developing and commercializing innovative medicines in areas of unmet medical needs, including HIV, viral hepatitis, oncology, and inflammation. 

**1. Performance Comparison:**

Gilead Sciences (GILD) has underperformed the S&P 500 (VOO) significantly. As of today, GILD has a cumulative return of 20.42%, while VOO has returned 88.56%. This results in a divergence of -68.14%, placing GILD in the 21.78% percentile of historical performance relative to VOO.

**2. Recent Price Movements:**

* **Closing price:** $83.14
* **5-day moving average:** $82.64
* **20-day moving average:** $79.18
* **60-day moving average:** $74.64

The stock price is currently above all three moving averages, indicating a potential upward trend.

**3. Technical Indicators:**

* **RSI:** 78.58 - This suggests that the stock is currently in overbought territory, which may signal a potential short-term correction.
* **PPO:** 0.37 - A positive PPO indicates potential upward momentum.
* **Delta_Previous_Relative_Divergence:** 10.36 - This signifies a recent short-term upward price movement relative to the historical trend. 
* **Expected_Return:** 19.82% - This represents the estimated potential return for the next 5 years based on the current investment amount.

**4. Recent Earnings and Outlook:**

| Date        | EPS | Revenue |
|-------------|-----|---------|
| 2024-08-08 | 1.29 | 6.95 B$ |
| 2024-05-08 | -3.34 | 6.69 B$ |
| 2023-11-07 | 1.75 | 7.05 B$ |
| 2023-08-04 | 0.84 | 6.60 B$ |
| 2024-08-08 | 0.84 | 6.60 B$ |

Gilead's most recent earnings report (2024-08-08) showed an EPS of 1.29, exceeding the analysts' estimates. This suggests positive momentum in the company's performance. However, it's important to note the significant fluctuation in EPS over the past year. 

**5. Overall Analysis:**

Gilead Sciences is currently trading at an overbought level, with a potential for a short-term correction. However, the recent earnings performance and positive technical indicators suggest potential upward momentum in the long term. The company has shown resilience and is capitalizing on its portfolio of existing products while exploring new avenues for growth. The significant underperformance compared to the S&P 500 could be a concern for investors, but the recent positive developments might indicate a potential turnaround. 

**6. Recommendations:**

* **Short-Term:** Given the current overbought condition, investors may want to exercise caution and consider a wait-and-see approach to observe potential short-term corrections. 
* **Long-Term:** Gilead Sciences has a solid foundation with a strong portfolio of products and a promising pipeline. Investors with a long-term horizon might find it attractive, given the company's focus on innovation and its potential to deliver strong returns. 

**Disclaimer:** This is just a brief analysis and does not constitute financial advice. Investors should always conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
